Atreca Inc BCEL

Alternate Symbol(s): COLUF

Atreca, Inc. is a clinical-stage biopharmaceutical company. The Company is discovering and developing antibody-based therapeutics to treat a range of solid tumor types. Its most advanced product candidate, ATRC-101, is a monoclonal antibody with a mechanism of action and target derived from an antibody identified using its discovery platform. ATRC-101 reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal and breast cancer samples from multiple patients. It commenced clinical development of ATRC-101 with a Phase Ib clinical trial evaluating ATRC-101 as a monotherapy in patients with select solid tumors and opens a new cohort to evaluate ATRC-101 in combination with pembrolizumab, a PD-1 checkpoint inhibitor. It is also advancing additional product candidates using its discovery platform. Its oncology programs include APN-497444, an ADC against a tumor glycan target, and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target.

PINL:BCEL - Post by User

Atreca Inc

Bullboard Posts

Post by TheHoboon Mar 16, 2010 11:29am

189 Views

Post# 16887568

l2

Orders/Shares

Price

Shares/Orders

4 / 1800	6.57	6.58	4200 / 3
3 / 2900	6.56	6.59	3600 / 4
1 / 1000	6.55	6.6	12400 / 8
2 / 1900	6.54	6.61	4300 / 2
1 / 1000	6.53	6.62	1600 / 2
1 / 1000	6.52	6.63	9800 / 3
1 / 100	6.51	6.65	2300 / 3
3 / 11600	6.5	6.67	1000 / 1
1 / 1000	6.49	6.68	500 / 1
2 / 4200	6.48	6.69	2000 / 2
3 / 1900	6.45	6.7	2000 / 3
1 / 1000	6.43	6.72	2200 / 3
1 / 500	6.42	6.73	10400 / 2
1 / 1000	6.41	6.75	2000 / 1
3 / 5500	6.4	6.78	2500 / 1
2 / 1100	6.36	6.8	10900 / 2
2 / 9900	6.35	6.84	400 / 1
3 / 4400	6.3	6.9	500 / 1
1 / 1800	6.28	6.98	1000 / 1
1 / 7000	6.26	6.99	1000 / 1